- In August 2023, the U.S. FDA continued to support the widespread use of Ciprofloxacin Ophthalmic Solution in pediatric patients following a comprehensive safety review spanning data from 1990 to 2023. The analysis found no new safety concerns in children under 17, reinforcing the drug's safety and efficacy in treating bacterial eye infections in pediatric populations. Additionally, multiple generic versions of Ciprofloxacin Ophthalmic Solution—manufactured by companies such as Altaire Pharmaceuticals, FDC Ltd., Rising, Rubicon, and Watson Labs—remain available in the U.S. market, with FDA approvals ranging from 2004 to 2018. This robust generic presence supports treatment accessibility and affordability across healthcare settings
